Gold Silver Reports (GSR) – Biocon Stock Declines After FDA Issues Form 483 – Shares of the Bengaluru-based pharma company fell as much as 4.5 percent, most in almost two months, to Rs 634.3. The U.S. drug regulator issued form 483 with seven observations after completing pre-approval inspection of the company’s sterile drug product manufacturing facility at Bengaluru this week, according to the company’s exchange filing. Observations are largely procedural and not critical, aiming at continuous improvement, it added.
